(2015) described the development of angiotensin IV analogs including Dihexa and their HGF/c-Met potentiation mechanism (PMID: 25455861) Expression of Concern: The landmark 2012 paper describing Dihexa's cognitive effects received an expression of concern from the journal (PMID: 34551989), citing data integrity issues including questioned Western blot images Retraction: A follow-up paper from the same research group was retracted (PMID: 40312093), further undermining the evidence base for Dihexa's reported effects No Human Studies: No clinical trials, pharmacokinetic studies, or safety assessments have been conducted in humans Limited Independent Replication: The core claims about Dihexa's cognitive-enhancing effects have not been independently replicated by groups outside the original laboratory The Evidence Gap: This comparison starkly illustrates the difference between a compound with decades of clinical validation (Cerebrolysin) and one with provocative preclinical data undermined by integrity concerns (Dihexa)
Those individuals also experienced greater reductions in liver fat than participants whose biological aging accelerated
Its interesting too to see conventional and fast food chains hedge against whats coming with the launch of new concepts like Chick-fil-As Daybright Coffee & Refreshment
Can nurse practitioners and physician assistants get semaglutide training
Many traditional small molecule drugs, such as glimepiride, metformin, and acarbose, help to control blood sugar levels
For nutraceutical manufacturers and formulators exploring high-potency product formats, the study provides baseline safety data beyond the standard 600 mg/day therapeutic dose
